- Home
- RCKT vs DFIN Comparison
RCKT vs DFIN Comparison
Compare RCKT & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKT | DFIN |
|---|---|---|
| Founded | 1999 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.9M | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RCKT | DFIN |
|---|---|---|
| Price | $3.44 | $45.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | $29.12 | ★ $63.50 |
| AVG Volume (30 Days) | ★ 1.9M | 279.4K |
| Earning Date | 11-06-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | N/A | ★ $750,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.20 |
| P/E Ratio | ★ N/A | $40.66 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.19 | $37.80 |
| 52 Week High | $13.35 | $69.93 |
Technical Indicators
Market Signals| Indicator | RCKT | DFIN |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 44.54 |
| Support Level | $3.36 | $45.71 |
| Resistance Level | $3.64 | $47.86 |
| Average True Range (ATR) | 0.18 | 1.22 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 56.18 | 43.88 |
Price Performance
Historical ComparisonAbout RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.